Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres.

Ranta, Susanna; Motwani, Jayashree; Blatny, Jan; Bührlen, Martina; Carcao, Manuel; Chambost, Hervé; Escuriola, Carmen; Fischer, Kathelijn; Kartal-Kaess, Mutlu; de Kovel, Marloes; Kenet, Gili; Male, Christoph; Nolan, Beatrice; d'Oiron, Roseline; Olivieri, Martin; Zapotocka, Ester; Andersson, Nadine G; Königs, Christoph (2023). Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres. Haemophilia, 29(5), pp. 1291-1298. Wiley 10.1111/hae.14847

Preview

Text Haemophilia_-_2023_-_Ranta.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (311kB) | Preview

INTRODUCTION

Haemophilia A care has changed with the introduction of emicizumab. Experience on the youngest children is still scarce and clinical practice varies between haemophilia treatment centres.

AIM

We aimed to assess the current clinical practice on emicizumab prophylaxis within PedNet, a collaborative research platform for paediatricians treating children with haemophilia.

METHODS

An electronic survey was sent to all PedNet members (n = 32) between October 2022 and February 2023. The survey included questions on the availability of emicizumab, on the practice of initiating prophylaxis in previously untreated or minimally treated patients (PUPs or MTPs) and emicizumab use in patients with or without inhibitors.

RESULTS

All but four centres (28/32; 88%) responded. Emicizumab was available in clinical practice in 25/28 centres (89%), and in 3/28 for selected patients only (e.g. with inhibitors). Emicizumab was the preferred choice for prophylaxis in PUPs or MTPs in 20/25 centres; most (85%) started emicizumab prophylaxis before 1 year of age (30% before 6 months of age) and without concomitant FVIII (16/20; 80%). After the loading dose, 13/28 centres administered the recommended dosing, while the others adjusted the interval of injections to give whole vials. In inhibitor patients, the use of emicizumab during ITI was common, with low-dose ITI being the preferred protocol.

CONCLUSION

Most centres choose to initiate prophylaxis with emicizumab before 12 months of age and without concomitant FVIII. In inhibitor patients, ITI is mostly given in addition to emicizumab, but there was no common practice on how to proceed after successful ITI.

Interest & Impact

Downloads

39 since deposited on 31 Aug 2023
39 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item